SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for recurrent or metastatic cervical cancer: a clinical expansion cohort of phase 1 study.

Ji-Feng FengDihong TangJing WangQi ZhouJin PengHanmei LouYuping SunYunlang CaiHongmin ChenJunqin YangPan LiuLinna WangJianjun Zou

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

SHR-1701 exhibits encouraging antitumor activity and controllable safety in patients with recurrent or metastatic cervical cancer after platinum-based regimens, might providing another treatment option for this population.

Keyphrases

squamous cell carcinoma
small cell lung cancer
open label
transforming growth factor
cancer therapy
randomized controlled trial
study protocol
replacement therapy
metal organic framework